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Microfluidic chip has been integrated with capacitive biosensor based on 
mass-producible three-dimensional (3D) interdigital electrode arrays. To achieve the 
monitoring of biosensor preparation and the cardiac and periodontitis-related 
biomarkers, all the processes were detected in a continuously on-site way. Fabrication 
steps for Microfluidic chip bonded 3D interdigital capacitor to monitor biosensor 
include gold thiol modification, the activation of EDC/sulfo-NHS, and the 
bioconjugation of antibodies. The fluorescent characterization and X-ray 
photoelectron spectroscopy analysis were applied to assess the successful 
immobilization of the C-Reactive Protein (CRP) antibody. The experimental results 
indicate the good specificity and high sensitivity of the Microfluidic integrated 3D 
capacitive biosensor. The limit of detection (LOD) of 3D capacitive biosensor for 
CRP label-free detection was about 1 pg·mL-1. This 3D capacitive biosensor with 
integrated Microfluidic is mass-producible and has achieved the on-site continuous 
detection of cardiac and periodontitis-related biomarkers with high performance.
Keywords: C-Reactive Protein; Capacitive biosensors; Microfluidic integration; 
Sulfhydryl modification; Electrochemical sensors; Biofunctionalization
1. Introduction
According to data from the World Health Organization (WHO), cardiovascular 
disease has become one of the leading causes of death globally 1,which posed a huge 
health threat and economic burden to the people. The risk of cardiovascular disease is 
always lurking in the development of the disease, and it may take several years to 
satisfy the diagnosis from sub-clinical state to clinical physical examination 2. The 
risk factors for cardiovascular disease are usually evaluated by family history, 
cholesterol and blood pressure levels3. However, the above risk factors are not 
sufficient as prognostic tools to predict the risk of cardiovascular disease4-6. The 
current detection method is difficult to achieve dynamic evaluation of the patient's 
physiological status, disease risk, and feedback on the efficacy of medication7, 8.
Biomarkers are a reliable and accurate auxiliary detection tool for screening 














































































































high-risk populations, predicting disease progression, and personalized diagnosis and 
treatment 9. Cardiovascular disease biomarkers can help to carry out screening, 
diagnosis, and prognostic assessment of cardiovascular related diseases. The 
increased levels of various biomarkers in the serum are related to the risk of 
cardiovascular disease in patients. i.e., CRP10, 11, interleukin-6 (IL-6) 12 and Brain 
natriuretic peptide (BNP) 10. Among them, CRP is an acute-phase protein secreted by 
cells during the process of inflammation stimulation with a subunit molecular weight 
of about 20-30 kD and a total molecular weight of about 115 kD13-15, which can cause 
adhesion molecules and inflammatory cells expression16. According to research, high 
CRP levels are associated with the risk of heart-related disease in patients with acute 
coronary syndrome11. In addition, as a biomarker, CRP plays an increasingly 
important role in the diagnosis of neonatal sepsis17, microangiopathy18 and cerebral 
embolism19 . 
The biomarkers contained in saliva participate in most physiological and 
pathological processes in the human body 20. Reichert Stefan and others have found 
that severe periodontitis can lead to increased CRP levels in the blood 21, The 
concentration of CRP in blood is related to the concentration of CRP in saliva 22, 23. At 
the same time, gingival crevicular fluid carries factors ingredients from serum and 
other components which related to oral microorganisms. Such as inflammatory 
mediators, antigens, etc. It can be collected noninvasively from the gingival sulcus or 
periodontal pocket by capillary action. Silvana P. Barros studies on biomarkers 
contained in gingival crevicular fluid indicate that gingival crevicular fluid has great 
research potential in disease diagnosis, prognosis and biomarkers24. Enzyme-linked 
immunosorbent assay (ELISA) is recognized as the standard method for the 
quantification of biomarkers in serum, which has been widely used in the detection of 
CRP25. The ELISA test method requires trained laboratory personnel to operate and 
has complex processes and high costs26.
Biosensors can be used to detect biomarkers with high sensitivity27. Among 
them, fluorescent biosensors were proposed to CRP detection28-30. As an auxiliary 
method, fluorescent labeling runs through ELISA and other common detection 














































































































processes. But it can cause carcinogenic risk of fluorescent substances 31. 
Improvements of label-based methods were urgently needed. It is well known that 
labeling is a time-consuming and high-cost process and may affect the interaction 
between receptor molecules and the analytes, especially regarding proteins 30. Among 
different label-free biosensors, capacitive biosensors are noted for the ease of 
fabrication and signal readout, low power consumption, flexible sensor sizes, high 
sensitivity and the ability of integration of the readout circuits in the sensor. These 
features make capacitive biosensors meet the requirements of medical testing at 
point-of-care testing (POCT), in a doctor’s office, a clinic, or even at home. 
Capacitive biosensors have ideal prospects for early diagnosis of diseases and 
potential disease risk detection32.
Several capacitive biosensors based on miniaturized two-dimensional (2D) 
surfaces with immobilized biorecognition were reported to detect the related targets 
successfully 8, 33-35. However, some limitations of 2D biosensors cannot be overlooked 
36. Firstly, the small surface area and surface area-to-volume ratio cause the reduced 
amount and therefore inefficient binding of specific targets and signal transduction, 
which may lead to instability of immobilized probes and low sensitivity. Moreover, 
the larger response time of 2D biosensors may be caused by the transportation 
diffusion, from analytes to the immobilized probe which only exists on a single 
surface. Furthermore, the effect of shear stress in a planar surface caused by sample 
loading can inhibit the bonding event between the analyte and the immobilized probe 
and will impose a significant impact on analytical performance.
In this work, the Microfluidic integrated mass-producible 3D interdigital 
capacitive biosensor was proposed to achieve the continuous on-site detection of 
cardiac and periodontitis-related biomarker with high performance. In order to reduce 
steric hindrance, the surface of the gold electrode is modified using mixed sulfhydryl 
molecules. The integrated Microfluidic channel for the capacitive sensor reduced the 
required sample amount for detection. In addition, the LCR instrument and the custom 
programs are used to set the detection experimental parameters and the real-time data 
acquisition, realizing the real-time monitoring of the capacitive biosensor’s 














































































































bio-modification and target protein detection. The Microfluidic integrated 3D 
capacitive biosensors have been implemented to detect the specific CRP biomarkers 
as well as nonspecific biomolecules, demonstrating high sensitivity, real-time, 
specificity, and label-free sensing performance. This method may provide a powerful 
POCT tool for low-abundance protein detection, assist in the assessment of the risk of 
coronary heart disease and other cardiovascular diseases in clinical diagnosis, and 
broaden the application of oral non-destructive testing.
2. Material and methods
2.1. Reagents and instruments 
Anti-CRP antibody, CRP antigen and myoglobin (MYO) antigen were purchased 
from Hytest Ltd. (Turku, Finland). Cytokeratin 19 (CK19) antigen and IL-6 antigen 
were purchased from Linc-Bio(Shanghai, China) and eBioscience Inc. (San Diego, 
USA),respectively.11-Mercaptoundecanoic acid, 6-Mercapto-1-hexanol, 
N-(3-Dimethylaminopropyl)-N′-ethyl carbodiimide hydrochloride (EDC), 
N-Hydroxysulfosuccinimide sodium salt (sulfo-NHS) and Streptomyces avidin 
(Cy3-SA) were got from Sigma (St. Louis, MO, USA). Phosphate-buffered saline 
(PBS, pH=7.2-7.4) were obtained from Sangon Biotech Co., Ltd. (Shanghai, China). 
Absolute ethanol were purchased from Lingfeng Chemical Reagent Co., Ltd. 
(Shanghai, China). Bovine Serum Albumin (BSA)was obtained from Equitech-Bio 
(Texas, USA). SU8 Negative Epoxy Resists was supplied by Kayaku Advanced 
Materials, Inc. (USA). Polydimethylsiloxane (PDMS) was obtained from Dow 
Corning Co., (NY, USA). BX51TRF microscope (Olympus Corporation, Japan) was 
used to characterize surface fluorescence modification of electrodes. X-ray 
photoelecgon spectroscopy (Thermo Fisher, USA) was used to verify the chemical 
modification of the electrodes. Precision LCR Meter E4980A (KEYSIGHT, USA) 
were used to measure the capacitive sensor. Millipore-Q purification system 
(Millipore, USA), was used to obtain deionized water for the preparation of all 
solutions. General serum diluent(GSD) were purchased from Immunochemistry 
Technologies (Minnesota, USA).














































































































2.2 Fabrication of Microfluidic integrated 3D capacitive biosensors
The proposed 3D capacitive devices were fabricated by using the open cavity 
molding method based on the integrated circuit package lead frames37. After 3D 
interdigital electrodes were soldered on the printed circuit board (PCB), the BNC 
were assembled on both sides of PCB for the connection with the LCR instrument. 
The Microfluidic integrated 3D capacitive biosensor was fabricated as the following 
step. First, the SU8 photoresist was spin-coated onto the silicon wafer and patterned 
by photolithography. Second, the patterned silicon wafer may be step hard-baked 
between 170°C on a hot plate. Further, polydimethylsiloxane (PDMS) was prepared at 
a 10:1 (w/w) ratio of prepolymer to cross-linker and poured over the silicon master. 
After curing (incubation at 95°C for 1 h), the PDMS slab was peeled off and punched 
to create inlet/outlet ports. Finally, the PDMS slab was firmly bonded to an 
interdigital capacitive device by plasma treatment.
2.3 Biofunctionalization of 3D capacitive Biosensors 
The integrated Microfluidic components provided low volume reagents for the 
construction of biosensor. Thiol mixtures, including 6-Mercapto-1-hexanol and 
11-mercaptoundecanoic acid, were injected into the Microfluidic channel to 
functionalize 3D interdigital Au electrode arrays by utilizing syringe pump. The 
functionalization of different thiol molecules could improve accessibility for protein 
immobilization due to reduced steric hindrance38. Then, EDC and sulfo-NHS were 
used to activate the carboxyl group functionalized gold surface to form the ester 
group. Finally, CRP antibodies were introduced into the Microfluidic channel and 
incubated at room temperature to achieve the biofunctionalization of the 3D 
capacitive sensor.
2.4 Characterization of 3D biosensor surface functionalization 
First, the fluorescent characterization of the 3D capacitive biosensor was applied 
to verify the successful immobilization of 11-mercaptoundecanoic acid by using 
streptavidin with Cy3. The fluorescence intensity of the 3D interdigital electrode was 
recorded by a fluorescence microscopy. Next, X-ray Photoelectron Spectroscopy 














































































































(XPS) analysis was used to characterize the surface composition of the functionalized 
gold electrodes in each step of the functionalization process. Thereafter, 
measurements of the dielectric parameters were performed at various steps of 
biosensor construction.      
The capacitance change was recorded in each step of the functionalization 
process. The bio-functionalization process of 3D capacitive device includes: (a) 
Mixed thiol functionalization of gold electrode; (b) Carboxyl activation by 
EDC/sulfo-NHS; (c) Anti-CRP bioconjugation.
2.5 Measurements of the3D capacitive biosensor.
The Keysight LCR meter was applied to connect the 3D capacitive device and 
recorded the capacitance by utilizing the custom software for fully automatic 
multi-group testing on the computer. The capacitance changes of the 3D capacitive 
device based on the integration of Microfluidic channel and the injection of PBS 
buffer were measured by LCR meter. The specificity of the 3D capacitive biosensor 
was verified by monitoring the response under different protein solutions.   
     The different concentrations of CRP antigen were pumped into the microfluidic 
channel of integrated 3D capacitive biosensor, which changed the dielectric constant 
of 3D capacitive biosensor. The measurement system of the microfluidic chip 
integrated 3D capacitive biosensor was shown in Figure 1.














































































































Figure 1: Micrograph of 3D interdigital electrode arrays (upper left), the photograph of 
Microfluidic integrated 3D capacitive biosensors (upper right) and the photograph of the measure 
system for the Microfluidic integrated 3D Capacitive Biosensor (lower).
3.Results & Discussion
3.1 Integration of Microfluidic chip and capacitive biosensor
Silicon wafers were photolithographically patterned using SU8-3050 photoresist. 
The steps are: Firstly, the SU8-3050 photoresist was spun on a silicon wafer at 1000 
rpm. Secondly, The SU8-3050 photoresist coated wafer was baking on a hot plate. 
During the pre-baking, the temperature of the hot plate was set at 65 °C, and then the 
temperature of the hot plate was gradually increased to 95 °C at intervals of 5 °C. This 
baking process last for 45 min and the hot plate was turned off, then naturally cool it 
down to room temperature. Thirdly, the SU8-3050 photoresist coated wafer was 
exposed for 2 min. After the exposure, the photoresist coated was placed on a hot 
plate. After 5 min of post exposure bake at 95 °C, an image of microfluidic channel 
was visible on the surface of SU8 3050 photoresist. Turn off the power, and naturally 
cool it down to room temperature, and complete the post-baking step. After naturally 
cool to room temperature, the exposed silicon wafer was developed in Propylene 














































































































glycol methyl ether acetate (PGMEA) for 4 min. Finally, the resist was hard baked on 
a hot plate at 170 °C for 30 min to further cross-link the material. 
To facilitate the bonding of the Microfluidic channel with the capacitor, a thin 
layer of PDMS was evenly applied on the PCB of the capacitor and cured in an oven 
for several minutes. Then the Microfluidic channel was bonded to the PDMS coated 
capacitor with 5 min plasma treatment. The integration of Microfluidic chip and 
capacitor and physical picture after red ink is injected into the Microfluidic channel 
were shown in FigureS1.
3.2 Construction of 3D capacitive biosensor 
Figure 2 Schematic of functionalizing process of 3D capacitive biosensor.
The biofunctionalization of 3D capacitive biosensor was shown in Figure 2. 
Firstly, the mixed sulfhydryl molecules (11-Mercaptoundecanoic acid and 
6-mercapto-1-hexanol) dissolved in absolute ethanol was injected into Microfluidic 
channels of the capacitor and incubated on the surface of the 3D interdigital electrode 
overnight. After finishing the uncombined sulfhydryl molecules were removed by 
absolute ethanol. The sulfhydryl groups of the mixed sulfhydryl molecules were 
bonded to the gold electrodes and at the same time 11-mercaptoic acid provided 
carboxyl group for the immobilization of anti-CRP. In addition, 
6-mercapto-1-hexanol was used to increase the steric hindrance of the functionalized 
surface, which could enhance the efficiency of the functionalization of subsequent 
antibodies. Secondly, a mixture of 0.1 M EDC and 0.1 M sulfo-NHS solution was 
introduced into the surface of sulfhydryl functionalized 3D interdigital electrode. The 














































































































carboxyl groups on the surface of the gold electrodes were activated into an ester 
group. 
After the completion of the above process stpes, the anti-CRPs solutions with the 
concentration of (100 ng·mL-1) were injected into the integrated Microfluidic channel 
of the 3D capacitor and incubated for 1 hour. Then the unbound anti-CRPs were 
removed by the PBS. Finally, 10% BSA was added to block the free sites on the 
surface of the anti-CRP functionalized electrodes for 30 min. After the blocking 
process was completed, deionized water was injected into the Microfluidic channel to 
remove the remaining BSA molecules. All the functionalization processes were 
performed at room temperature. The prepared 3D capacitive biosensor was stored at 
4 °C in the refrigerator. 
3.3 Characterization of the gold electrode functionalization by XPS
Figure 3(a) XPS O1s spectra of the bare gold electrode, mixed thiol molecules functionalized gold 
electrode, the treatment of EDC and sulfo-NHS and the immobilization of anti-CRP;(b) XPS Au 
spectra of the bare gold electrode, mixed thiol molecules functionalized gold electrode, the 
treatment of EDC and sulfo-NHS and the immobilization of anti-CRP.
The XPS analysis was utilized to explore the surface elements composition of the 
gold electrodes in each step of the functionalization process, including the bare gold 
electrode, mixed thiol molecules functionalized Au electrode, the treatment of EDC 
and sulfo-NHS and the immobilization of anti-CRP Au electrode.
The change of oxygen element during the surface functionalization of gold 
electrodes was recorded in Figure 3(a). After the self-assembly of mixed sulfhydryl 














































































































molecules, due to the carboxyl groups and hydroxyl groups of mixed sulfhydryl 
molecules, the peak of O1s shift from 532.32eV to 532.59eV and the intensity of this 
peak significantly increased. After the treatment of EDC and sulfo-NHS, the carboxyl 
group on the surface of the gold electrode was activated to an ester intermediate, and 
blue shift (about 0.52eV) was observed in the peak of O1s. Finally, after the 
immobilization of antibodies, the ester intermediate on the surface of the gold 
electrode was reacting with amine-containing anti-CRP, and the oxygen binding 
energy is found in the spectrum at 532.36eV. The amide bond formation led to lower 
the intensity of the peak of O1s as shown in Figure 3(a). XPS O1s spectra of Au 
electrode shown in Figure 3(a) indicated the successful immobilization of thiol 
mixture, EDC/sulfo-NHS and anti-CRP. 
In addition, the XPS of the gold element was recorded in the bare gold electrode, 
mixed sulfhydryl molecules functionalized Au electrode, and the treatment of 
EDC/sulfo-NHS and the immobilization of anti-CRP, which was shown in Figure 
3(b). While the surface of the gold electrode was gradually covered by the mixed 
sulfhydryl molecules and the EDC/sulfo-NHS, the intensity of the Au peak decreased 
gradually. Furthermore, the immobilization of anti-CRP was caused a slight increase 
in the intensity of the Au peak. All of these results demonstrated the obvious change 
in the coverage of the gold electrodes due to the biofunctionalization of 3D 
interdigital electrodes (as shown in Figure 3). Further ， XPS Au spectra of Au 
electrode was about 83.6eV after the activation of EDC and sulfo-NHS and the 
immobilization of anti-CRP.
Mixed sulfhydryl molecules (6-Mercapto-1-hexanol and 11-mercaptoundecanoic 
acid) were introduced into the Microfluidic channel and incubated for 12 hours at 
room temperature. The change of nitrogen element during the surface 
functionalization of gold electrodes was recorded in Figure S2. The experimental 
results of XPS indicated the changes in surface element composition of 3D interdigital 
electrodes caused by the functionalization.
3.4 Fluorescent characterization of the biofunctionalization of gold electrodes














































































































Figure 4 Fluorescent characterization of biofunctionalization of gold electrodes. Clustered 
fluorescent spots can be observed in the experiment group electrode photos after biological 
modification and antibody incubation. The dark field image of the control group electrode hardly 
changes before and after the antibody incubation.
To verify the immobilization of antibody via mixed sulfhydryl molecules and 
EDC/sulfo-NHS, streptavidin-Cy3 with the concentration of 1ug·mL-1 was injected 
into the surface of 3D gold electrodes after the activation of EDC and sulfo-NHS and 
incubated for 1 hour. In the experiment, photos of electrodes from the bright field and 
dark field, before and after biological modification were collected in the same channel 
and exposure time. 
The experimental results were observed by comparing the electrode photos of the 
experimental group and the control group, as shown in Figure 4. Bright and clustered 
fluorescent spots can be observed in the electrode photos after biological modification 
and antibody incubation, despite of the fluorescence interference from the electrode 
gap. The fluorescence interference caused by the epoxy resin, which were used to 
package the 3D interdigital electrodes. At the same time, because the control group 
does not have a chemical group that can bind with the fluorescent antibody, the dark 
field image of the electrode showed little difference before and after the antibody 
incubation. The similar electrode images at a higher magnification of the microscope 














































































































were as shown in Figure S3. Fluorescent images of the functionalized gold electrodes 
indicated the effectiveness of biofunctionalization based on the mixed sulfhydryl 
molecules and EDC/sulfo-NHS.
3.5 Performance test of capacitive biosensors
Figure 5(a) The capacitance of five 3D interdigital capacitors before and after integrating 
Microfluidic chip; (b) Capacitance changes before and after PBS injection.
Five different 3D capacitors were measured at the voltage of 0.1V under 
different frequencies. The capacitance of five devices decreased with the frequencies 
in Figure 5(a), which demonstrated the good consistency of these 3D interdigital 
capacitors. The measured capacitance of five devices before and after integrating 
Microfluidic chip in Figure 5(a) also indicated the Microfluidic chip bonding has little 
effect on the fluctuation of the capacitance data. After the integration of the 
Microfluidic chip, the capacitance was recorded during the PBS injection as shown in 
Figure 5(b). 
Figure 6 (a) The on-site monitoring of the thiol mixtures self-assembled on Au surface under 














































































































different frequencies; (b) The on-site monitoring of 3D interdigital capacitor after the treatment of 
the thiol mixtures, EDC/sulfo-NHS and anti-CRP. 
Each step of the functionalization process of the gold electrodes was on-site 
monitored by the LCR meter. Figure 6(a) shows the bonding process between mixed 
sulfhydryl molecules and gold electrodes, the treatment of EDC/sulfo-NHS and the 
covalent binding of anti-CRP resulted in the change of the capacitance as is shown in 
Figure 6(b). The total molecular weight and surface charge of 3D interdigital 
electrodes after the biofunctionalization may influence the response of the capacitor 
biosensor, which need further investigate in the future work.
3.6 Specificity and sensitivity of Microfluidic integrated 3D capacitive biosensor 
Figure 7 (a) Net capacitance responses to control group, CK19, MYO, IL-6, and CRP. (b) On-site 
continuous monitoring: the change of the capacitance value of the electric sensor as the CRP 
protein concentration increases.
To verify the specificity of the biosensor, CK19, MYO, IL-6 and PBS were 
injected into the Microfluidic channel as control groups. The concentration of all 
these proteins was 100 ng·mL-1. In particular, to avoid interfering with the interaction 
between the antigens, after each test of each antigen, the PBS buffer is introduced to 
wash the remaining reagent in the inlet and outlet tubes and the Microfluidic channel. 
The average value of the capacitance value obtained by the PBS test is used for data 
standardization, so as to obtain the analysis statistics of the capacitance increase in the 
specific test. The net capacitance increment verifies the specificity of the sensor, and 
the statistical result is shown in Figure7(a). The capacitance value of CRP antigen of 














































































































3D capacitive biosensors was obviously higher than that of control groups. Among 
them, the capacitance increases when interfering with protein detection may be caused 
by the non-specific adsorption of the protein on the electrode surface. It can be 
concluded that when antibody-antigen specific binding occurs on the sensor surface, 
the dielectric constant increases. In summary, the anti-CRP functionalized 3D 
capacitive biosensor exhibited high specificity for the detection of CRP. 
To evaluate the sensitivity of the 3D capacitive biosensor, the CRP antigen 
solution dissolved in PBS buffer with 6 different concentrations (1, 10, 
100,1000,10000,100000 pg·mL-1) was injected into Microfluidic integrated 3D 
capacitor sequentially. The LCR meter controlled by custom software, set at the 
voltage of 200mV with different frequencies (from 20Hz to 1.5MHz). The 
capacitance values were real-time monitored by the LCR meter as shown in Figure 
7(b). The capacitive values recorded by 3D capacitive biosensor were positively 
correlated with the concentrations of CRP antigen. The relationship between 
capacitance changes and CRP concentration (logarithm) is shown in Figure 8(a). As 
shown in this figure, based on the fitted curve, the correlation coefficient (R2) was 
above 0.99, which indicates a high correlation between the curve and experiment 
results. The red line provides the best Langmuir model fitting of the experimental 
data. The Langmuir model is valid for monolayer sorption to a surface with a finite 
number of identical sites, which have been widely utilized in different biosensors 39-41.
These data were plotted to a nonlinear curve, indicating that the relationship 
between ∆F and the binding CRP could fit the Langmuir adsorption model described 
as follows:
∆𝐹 = ∆𝐹𝑚𝑎𝑥𝐶crp/(𝐾𝑑 + 𝐶crp)
Where  is the dissociation constant of the interaction between CRP and Kd
anti-CRP, is the protein concentration,  is the saturated capacitance and𝐶𝑐𝑟𝑝 ∆𝐹𝑚𝑎𝑥  ∆
denotes net capacitance value. According to the fitting results, the value of saturated 𝐹
capacitance  was calculated to be about 2.12nF. The dissociation constant ( ) ∆𝐹𝑚𝑎𝑥 𝐾𝑑
of the interaction between the anti-CRP antibody and CRP can be estimated by 
measuring the capacitance at different CRP concentrations, which was estimated to be 














































































































0.024 ng·mL-1. The limit of detection (LOD) of 3D capacitive biosensor was 
estimated by the total of the means of the blank response and 3 times standard 
deviation of the blank response.
Figure 8 (a) Label-free detection of CRP with anti-CRP immobilized 3D capacitor, the red line is 
the best Langmuir model fit curve; (b) Net capacitance increment with different CRP 
concentrations in diluted serum sample under different capacitor working frequencies.
3.7 Detection with the serum sample
The clinical serum sample with known CRP concentrations (tested by ELISA 
kit) were utilized to validate the performance of this integrated capacitive biosensor. 
Due to the high CRP concentration in this sample (the level of micrograms per 
milliliter) and the high viscosity of serum sample (which may block the microfluidic 
channel), GSD was chosen as a dilution reagent to dilute the CRP concentration in the 
sample to several specified concentrations (10,100,1000ng·mL-1). The diluted serum 
was measured by this integrated 3D capacitive biosensor with different capacitor 
working frequencies (100kHz, 500kHz and 1000kHz), as shown in Figure 8(b). The 
average of capacitance values obtained from the detection of GSD solution is used for 
data normalization. As working frequencies increased, the response difference of this 
biosensor at different concentrations decreased obviously, which indicated the lower 
working frequency was more suitable for biomolecules detection. 
As the similar responses of this integrated 3D biosensor in PBS, the capacitance 
increased with the CRP concentration in the serum sample. The experimental results 
could be also fitted with the Langmuir model and the details information about the 














































































































calculated parameters was shown in Figure S4. The stable and effective responses in 
serum of this integrated 3D biosensor means the possibility of clinical application for 
this biosensor. The difference responses in PBS and serum for this biosensor may 
attributed to the adsorption of unspecific biomolecules in the complex serum samples.
4.Conclusions
The proposed fully symmetric 3D interdigital electrode arrays were fabricated by 
using the open cavity molding method based on the integrated circuit package lead 
frames. The Microfluidic components has been integrated with 3D capacitive 
biosensor to create low sample required and surface shear stress controllable sensing 
devices with the aid of the syringe pump. The 3D interdigital Au electrode arrays 
were modified by various thiol mixtures of 6-Mercapto-1-hexanol and 
11-mercaptoundecanoic acid, the results of XPS and fluorescent characterization of 
the biofunctionalized gold electrodes indicated the successful immobilization of 
Anti-CRP. Different concentrations of CRP protein in PBS and diluted serum were 
injected into the integrated microfluidic channel by a syringe pump, which were 
continuously monitored by the LCR meter. The LOD of this integrated 3D capacitive 
biosensor could reach 1pg·mL-1 in PBS. The effective responses in serum of this 
integrated 3D biosensor provided the possibility of clinical application for 
cardiovascular and periodontitis-related biomarkers detection.  
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The mixed thiol molecules are used to carboxylate the electrode surface to reduce the 
steric hindrance during antibody binding.
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